Get the Daily Brief
Latest Biotech News
10x Genomics scales single‑cell: next‑gen Flex brings plate multiplexing
10x Genomics launched the next generation of its Chromium Flex assay that scales single‑cell studies by enabling automation‑compatible plate‑based multiplexing—processing up to 384 samples and...
Thermo Fisher moves to acquire Clario: $8.9B cash deal
Thermo Fisher Scientific agreed to acquire data‑solutions company Clario for $8.9 billion in cash plus an additional $125 million contingent payment—bringing the deal to about $9.0–$9.4 billion...
Novo’s $9B Shock: Metsera Deal Sparks Antitrust Clash
Novo Nordisk made a surprise unsolicited bid that values Metsera at roughly $9 billion, prompting Metsera’s board to deem the proposal “superior” to Pfizer’s earlier agreement and giving Pfizer...
FDA Signals Faster Biosimilar Path: Trials Could Be Cut
The U.S. Food and Drug Administration unveiled draft guidance and public statements aimed at trimming clinical requirements for biosimilars, proposing reduced reliance on comparative efficacy...
FDA Halts Intellia CRISPR Phase 3 Trials After Liver Signal
The U.S. Food and Drug Administration placed an official clinical hold on two Phase 3 trials of Intellia Therapeutics’ in vivo CRISPR candidate following a serious liver injury in a study...
Lilly’s GLP-1 Machine: Revenue Surge and New Pill Factory
Eli Lilly reported blockbuster third-quarter sales for tirzepatide products, prompting the company to raise its revenue outlook and plan a $1.2 billion factory in Puerto Rico to scale production...
Thermo Fisher to Buy Clario: $8.9B Data Play
Thermo Fisher Scientific announced a cash acquisition of Clario, a clinical-trial data solutions company, in a transaction valued at roughly $8.9 billion plus contingent payments. Thermo Fisher is...
10x Genomics Scales Single‑Cell: Flex 384‑Plate Pushes Throughput
10x Genomics launched a next-generation Chromium Flex assay that expands plate-based multiplexing to 384 samples and promises throughput up to hundreds of millions of cells per week. Early-access...
BridgeBio’s Late‑Stage Wins: Encaleret Clears Phase III Threshold
BridgeBio reported positive Phase III results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1), meeting primary and key secondary endpoints with a high proportion of patients...
Recursion Maps Microglia — Roche Pays $30M Milestone
Recursion delivered a whole‑genome microglia phenomap generated from tens of millions of cell images to Roche and Genentech under their AI drug‑discovery pact, triggering a $30 million milestone...
Gilead’s Cell Therapy Pullback and Lenacapavir Partner Move
Gilead reported an 11% year‑over‑year decline in cell therapy revenue for marketed CAR‑T products and disclosed a strategic decision in its early‑stage lenacapavir program: after comparing two...
Price Versus Access: GLP‑1 Economics and Retail Partnerships
New analyses and commercial moves are reshaping how GLP‑1 medicines reach patients: a health‑economics review found potency and outcomes justify higher prices for weight‑loss GLP‑1s under some...
FDA places formal hold on Intellia’s Phase 3 CRISPR trials: liver‑safety signal
The U.S. Food and Drug Administration has placed a clinical hold on two Phase 3 trials of Intellia Therapeutics’ CRISPR candidate nexiguran ziclumeran after a participant experienced a grade‑4...
Novo Nordisk ups the ante: $9B bid challenges Pfizer for Metsera
Novo Nordisk submitted an unsolicited offer valuing obesity biotech Metsera at up to $9 billion—outbidding Pfizer’s earlier agreement—and the company’s board has labeled the proposal a “superior...
Lilly leans in: tirzepatide drives revenue and a $1.2B factory push
Eli Lilly reported blockbuster demand for tirzepatide, prompting a revenue forecast raise after the drug posted record quarterly sales. The company said tirzepatide (sold as Mounjaro/Zepbound)...
FDA proposes lighter path for biosimilars: trials may no longer be required
The U.S. Food and Drug Administration published draft guidance proposing to eliminate routine comparative clinical efficacy trials for many biosimilars, a move designed to speed approvals and...
Thermo Fisher to buy Clario for up to $9.4B: data play expands clinical services
Thermo Fisher Scientific agreed to acquire clinical‑trial data and software firm Clario in a cash deal reportedly worth about $8.9 billion plus earnouts. The transaction aims to integrate Clario’s...
HHS approves 340B rebate pilot participants: Merck, BMS and others join
The U.S. Department of Health and Human Services approved applications from eight drugmakers to participate in a pilot testing a new 340B reimbursement rebate model. The decision allows companies...
USDA clears first large‑scale cultivated meat facility: Believer Meats wins label and export access
Believer Meats announced USDA approval of its North Carolina cultivated‑chicken facility and product labeling, clearing the way for commercial production and U.S. sales as well as exports. The...
Illumina posts flat Q3 revenue, raises 2025 guidance: clinical segment supports recovery
Sequencing leader Illumina reported $1.08 billion in third‑quarter revenue—flat year‑over‑year—and beat adjusted EPS expectations, prompting a modest upward revision to its 2025 guidance....